These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34451981)

  • 21. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemplating HPV vaccination in Japan during the time of COVID-19.
    Miyoshi A; Ueda Y; Kimura T
    Hum Vaccin Immunother; 2021 Mar; 17(3):836-837. PubMed ID: 32961077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
    van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
    Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
    Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of health education on health science teachers' intention to recommend adolescent HPV vaccine for female students in Japan.
    Ishiwada N; Suzuki C; Hasebe S; Tsuchiya A; Takeuchi N; Hishiki H; Sato Y; Sugita K
    Hum Vaccin Immunother; 2020 Nov; 16(11):2752-2757. PubMed ID: 32159443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
    Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China.
    Liu Z; Zhang L; Yang Y; Meng R; Fang T; Dong Y; Li N; Xu G; Zhan S
    J Med Internet Res; 2020 Jun; 22(6):e17446. PubMed ID: 32234696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus vaccination and all-cause morbidity in adolescent girls: a cohort study of absence from school due to illness.
    Hviid A; Thorsen NM; Thomsen LN; Møller FT; Wiwe A; Frisch M; Valentiner-Branth P; Rytter D; Mølbak K
    Int J Epidemiol; 2021 May; 50(2):518-526. PubMed ID: 33547468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany.
    Rieck T; Feig M; Deleré Y; Wichmann O
    Vaccine; 2014 Sep; 32(43):5564-9. PubMed ID: 25131739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stopping the HPV vaccine crisis in Japan: Quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making.
    Kitano T
    J Infect Chemother; 2020 Mar; 26(3):225-230. PubMed ID: 31607433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data.
    Huygen F; Verschueren K; McCabe C; Stegmann JU; Zima J; Mahaux O; Van Holle L; Angelo MG
    EBioMedicine; 2015 Sep; 2(9):1114-21. PubMed ID: 26501109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving high uptake of human papillomavirus vaccination in Malaysia through school-based vaccination programme.
    Muhamad NA; Buang SN; Jaafar S; Jais R; Tan PS; Mustapha N; Lodz NA; Aris T; Sulaiman LH; Murad S
    BMC Public Health; 2018 Dec; 18(1):1402. PubMed ID: 30577816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
    Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
    Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan.
    Hayashi Y; Shimizu Y; Netsu S; Hanley S; Konno R
    Vaccine; 2012 Aug; 30(37):5547-50. PubMed ID: 22749837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.